Sanford C. Bernstein set a €105.00 ($129.63) target price on Merck KGaA (FRA:MRK) in a research report released on Wednesday morning. The brokerage currently has a buy rating on the healthcare company’s stock.
MRK has been the subject of a number of other research reports. UBS set a €120.00 ($148.15) price objective on Merck KGaA and gave the company a buy rating in a research report on Monday, January 8th. Nord/LB reissued a neutral rating on shares of Merck KGaA in a research report on Wednesday, December 27th. Warburg Research set a €115.00 ($141.98) price objective on Merck KGaA and gave the company a buy rating in a research report on Wednesday, March 7th. JPMorgan Chase & Co. set a €95.00 ($117.28) price objective on Merck KGaA and gave the company a neutral rating in a research report on Thursday, January 4th. Finally, Kepler Capital Markets set a €106.00 ($130.86) price objective on Merck KGaA and gave the company a buy rating in a research report on Monday, March 12th. Twelve research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has an average rating of Hold and an average price target of €100.55 ($124.13).
Shares of MRK stock opened at €75.60 ($93.33) on Wednesday. The stock has a market capitalization of $10,070.00 and a price-to-earnings ratio of 12.64. Merck KGaA has a 12-month low of €76.60 ($94.57) and a 12-month high of €115.00 ($141.98).
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.